Oral administration of 100 mg KH176 twice daily
Phase 2CompletedDevelopment Stage
Mitochondrial Diseases
Mitochondrial Diseases, Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation, Maternally Inherited Diabetes and Deafness (MIDD), Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke Like Episodes (MELAS), Chronic Progressive External Ophthalmoplegia (CPEO)
Aug 9, 2021 → Jun 1, 2023
About Oral administration of 100 mg KH176 twice daily
Oral administration of 100 mg KH176 twice daily is a phase 2 stage product being developed by Certara for Mitochondrial Diseases. The current trial status is completed. This product is registered under clinical trial identifier NCT04604548. Target conditions include Mitochondrial Diseases, Mitochondrial DNA tRNALeu(UUR) m.3243A<G Mutation, Maternally Inherited Diabetes and Deafness (MIDD).
What happened to similar drugs?
0 of 1 similar drugs in Mitochondrial Diseases were approved
Hype Score Breakdown
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04604548 | Phase 2 | Completed |
Competing Products
13 competing products in Mitochondrial Diseases
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| REN001 | OnKure Therapeutics | Phase 1 | 11 |
| Mavodelpar + Placebo | OnKure Therapeutics | Phase 2 | 25 |
| REN001 | OnKure Therapeutics | Phase 2/3 | 20 |
| Bocidelpar + Placebo | Astellas Pharma | Phase 2 | 27 |
| Omaveloxolone capsules, 2.5 mg + omaveloxolone capsules, 5 mg + omaveloxolone capsules, 10 mg + Placebo capsules + omaveloxolone capsules, 20 mg + omaveloxolone capsules, 40 mg + omaveloxolone capsules, 80 mg + omaveloxolone capsules, 160 mg | AbbVie | Phase 2 | 35 |
| Cysteamine Bitartrate | Amgen | Phase 2 | 27 |
| Cysteamine Bitartrate | Amgen | Phase 2 | 35 |
| Vatiquinone | PTC Therapeutics | Phase 2/3 | 27 |
| EPI-743 | PTC Therapeutics | Pre-clinical | 23 |
| RG2133 (2',3',5'-tri-O-acetyluridine) | Repligen | Phase 1 | 18 |
| Vatiquinone | PTC Therapeutics | Pre-clinical | 27 |
| Vatiquinone | PTC Therapeutics | Phase 3 | 37 |
| Sonlicromanol + Placebo | Certara | Phase 2 | 33 |